Aquestive Therapeutics, Inc. (AQST)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Aquestive Therapeutics, Inc. (AQST)
Company Performance

Current Price

as of Oct 16, 2024

$4.93

P/E Ratio

N/A

Market Cap

$448.92M

Description

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Metrics

Overview

  • HQWarren, NJ
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerAQST
  • Price$4.93+0.82%

Trading Information

  • Market Cap$448.92M
  • Float87.16%
  • Average Daily Volume (1m)1,236,216
  • Average Daily Volume (3m)1,265,905
  • EPS-$0.35

Company

  • Revenue$58.36M
  • Rev Growth (1yr)51.79%
  • Net Income-$2.74M
  • Gross Margin77.48%
  • EBITDA Margin1.29%
  • EBITDA$0.26M
  • EV$263.38M
  • EV/Revenue4.51
  • P/EN/A
  • P/S7.68
  • P/BN/A
Documents
SEC Filings
8-K (2024-10-16)
8-K (2024-09-27)
8-K (2024-09-09)
8-K (2024-08-14)
8-K (2024-08-06)
8-K (2024-07-25)
8-K (2024-06-21)
8-K (2024-06-07)
8-K (2024-06-06)
8-K (2024-05-08)
8-K (2024-05-07)
8-K (2024-04-29)
8-K (2024-04-22)
8-K (2024-04-01)
8-K (2024-03-21)
8-K (2024-03-15)
8-K (2024-03-05)
8-K (2023-12-08)
8-K (2023-12-05)
8-K (2023-11-08)
8-K (2023-11-06)
8-K (2023-11-02)
8-K (2023-10-10)
8-K (2023-09-20)
8-K (2023-08-11)
8-K (2023-08-07)
8-K (2023-08-02)
8-K (2023-07-27)
8-K (2023-06-29)
8-K (2023-06-23)
8-K (2023-05-31)
8-K (2023-05-02)
8-K (2023-04-13)
8-K (2023-03-13)
8-K (2023-03-07)
8-K (2023-03-06)
8-K (2023-02-07)
8-K (2023-01-24)
8-K (2023-01-03)
10-Q (2024-08-06)
10-Q (2024-05-07)
10-Q (2023-11-06)
10-Q (2023-08-07)
10-Q (2023-05-02)
10-K (2024-03-05)
10-K (2023-03-31)
Factset Street Account
Aquestive Therapeutics reports Q3 EPS ($0.03) vs FactSet ($0.11) [6 est, ($0.14)-(0.09)] ($1.63, 0.00) (2023-11-06T21:41:12Z)
Aquestive Therapeutics provides business update on lead pipeline programs and base business ($1.33, 0.00) (2023-10-09T12:04:25Z)
Aquestive Therapeutics announces completion of debt refinancing ($1.54, 0.00) (2023-11-02T12:11:58Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-07)
Earnings Report (2023-08-08)
Factset
Factset Business Description